from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A platelet aggregation inhibitor.


Sorry, no etymologies found.


  • Brilinta, also known as ticagrelor, was launched last year in Europe.

    Tax Provision Boosts AstraZeneca's Profits

  • Brilinta, also known by its generic name ticagrelor, is regarded as a key product for AstraZeneca to help offset expiring patents on some of the company's best-selling medicines including its antipsychotic drug Seroquel.

    FDA Approves Astra's Anticlotting Drug

  • Brilinta, also known by its generic name ticagrelor, is designed to keep blood platelets from sticking together in order to prevent blood clotsthat can lead to heart attacks and strokes.

    AstraZeneca Shares Rise on Drug's Approval

  • Brilinta, also known as ticagrelor, was launched last year in Europe and received marketing approval last week in the U.S. from the U.S. Food and Drug Administration, albeit with a boxed warning about a decrease in effectiveness if it's taken with more than 100 milligrams of aspirin a day and that Brilinta increases the risk of bleeding and can cause, at times, sometimes fatal bleeding.

    Generic Competition Hinders AstraZeneca

  • The U.S. Food and Drug Administration recently approved for sale a new AstraZeneca PLC cardiovascular drug called ticagrelor, a decision that once would have been the climactic moment in the launch of a new blockbuster drug.

    Hurdles Multiply for Latest Drugs

  • Brilinta, known by the generic name ticagrelor, isn't on the market.

    AstraZeneca Heart Drug

  • Brilinta, which is also known as ticagrelor, won a 7-1 vote in its favor from a U.S.

    Reuters: Top News

  • The FDA delayed a decision in December, asking for more analysis of the London-based AstraZeneca's Plato study comparing Brilinta, also known as ticagrelor, with Plavix, made by New York-based Bristol-Myers Squibb Co. and Paris-based Sanofi. -- Top News

  • The Food and Drug Administration cleared Brilinta, also known as ticagrelor, for use by patients with severe chest pain or heart-attack history to cut the risk of heart attacks, strokes and death, the agency said yesterday in a statement. -- Top News

  • The drug, also known as ticagrelor, was approved in Europe earlier this month and was recommended for approval in the United States by an F.D.A. advisory committee on a 7 to 1 vote in July.

    NYT > Home Page


Log in or sign up to get involved in the conversation. It's quick and easy.